logo
    Glucocerebrosidase activity and transport to lysosomes in primary macrophages from patients with mutations in the GBA gene
    0
    Citation
    0
    Reference
    10
    Related Paper
    Glucocerebroside
    Hepatosplenomegaly
    Gaucher's disease
    Substrate reduction therapy
    Lysosomal storage disease
    Lysosomal Storage Disorders
    Citations (53)
    Gaucher Disease (GD) is an autosomal recessive systemic lysosomal storage disorder, characterized by glucocerebroside deposition in cells of macrophage-monocyte system and accumulation of glucosylceramide in different organs as result of deficiency in lysosomal β-glycosidase (glucocerebrosidase).
    Glucocerebroside
    Gaucher's disease
    Monocyte
    For the diagnosis of homozygotes and heterozygotes of Gaucher disease, glucocerebrosidase (glucocerebroside beta-D-glucoside glucohydrolase, EC 3.2.1.45) activity in lymphocytes was measured using a fluorescent analogue of glucocerebroside, 1-0-glucosyl-2-N-(dimethylaminonaphthalene-5-sulfonyl)-sphingosine as substrate. The activity in lymphocytes from homozygotes of Gaucher disease was found to be reduced markedly. This method is proved to be simple, sensitive, and specific as an assay of glucocerebrosidase activity for the diagnosis of Gaucher disease.
    Glucocerebroside
    Gaucher's disease
    Sphingolipid
    Citations (4)
    Gaucher disease is the most common glycolipid storage disorder, characterized by storage of the glycolipid, glucocerebroside in the liver, spleen, and marrow. The most prevalent form of Gaucher disease is designated type I (MIM 230800). Patients with type I disease may have hepatomegaly, splenomegaly, bone lesions, and less commonly, lung disease, but are free of neurological involvement. Types II (MIM 230900) and III (MIM 2310000), the acute infantile and juvenile forms, respectively, of Gaucher disease, are characterized by the fact that the central nervous system is affected.
    Glucocerebroside
    Gaucher's disease
    Gaucher disease is a multisystemic disorder that affects men and woman in equal numbers and occurs in all ethnic groups at any age with racial variations and an estimated worldwide incidence of 1/75,000. It is caused by a genetic deficient activity of the lysosomal enzyme glucocerebrosidase due to mutations in the β-glucocerebrosidase gene, and resulting in lack of glucocerebroside degradation. The subsequent accumulation of glucocerebroside in lysosomes of tissue macrophages primarily in the liver, bone marrow and spleen, causes damage in haematological, skeletal and nervous systems. The clinical manifestations show a high degree of variability with symptoms that varies according to organs involved. In many cases, these disorders do not correlate with mutations in the β-glucocerebrosidase gene. Although several mutations have been identified as responsible for the deficient activity of glucocerebrosidase, mechanisms by which this enzymatic defect leads to Gaucher disease remain poorly understood. Recent reports indicate the implication of complex mechanisms, including enzyme deficiency, substrate accumulation, unfolded protein response, and macrophage activation. Further elucidating these mechanisms will advance understanding of Gaucher disease and related disorders.
    Glucocerebroside
    Gaucher's disease
    Citations (19)
    Gaucher disease is the most common glycolipid storage disorder, characterized by storage of the glycolipid, glucocerebroside in the liver, spleen, and marrow. The most prevalent form of Gaucher disease is designated type I (MIM 230800). Patients with type I disease may have hepatomegaly, splenomegaly, bone lesions, and less commonly, lung disease, but are free of neurological involvement. Types II (MIM 230900) and III (MIM 2310000), the acute infantile and juvenile forms, respectively, of Gaucher disease, are characterized by the fact that the central nervous system is affected. © 1996 Wiley-Liss, Inc.
    Glucocerebroside
    Gaucher's disease